The effects of repetitive peripheral magnetic stimulation on motor function and spasticity in patients with hemiparesis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

DRKS

Registry ID

DRKS00000798

Enrollment

Registered

2018-03-05

Start date

2007-04-21

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I64 S06.9

Interventions

Group 1: Treatment: 20-minute therapy sessions of repetitive peripheral magnetic stimulation (rpMS) plus an additional 20 minutes of occupational therapy, 2 times a day, 5 times a week, for 2 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: • hemiparesis after stroke or traumatic brain injury • grade 1 to 3 on Tardieu scale

Exclusion criteria

Exclusion criteria: • co-morbidity with other degenerative diseases • implanted medical devices, i.e. o cardiac pacemaker o Cochlea- implant • pregnancy • metal implants (head and/or stimulation area) • instabile fractures within stimulation area • pathological intracraniel pressure

Design outcomes

Primary

Measure	Time frame
Primary outcome parameter is the function and spasticity of the paretic upper extremity. The Fugl-Mayer assessment is used to assess function, and the Tardieu scale to assess spasticity. Both scales will be assessed before therapy, at the end of the 2-week treatment period, and 2 weeks after study treatment. Additionally the Tardieu Scale will be assessed after the first and before the third therapy session to determine any short-term effects.	—

Measure

Time frame

Primary outcome parameter is the function and spasticity of the paretic upper extremity. The Fugl-Mayer assessment is used to assess function, and the Tardieu scale to assess spasticity. Both scales will be assessed before therapy, at the end of the 2-week treatment period, and 2 weeks after study treatment. Additionally the Tardieu Scale will be assessed after the first and before the third therapy session to determine any short-term effects.

—

Secondary

Measure	Time frame
As secondary outcome the independance in activities of daily living, depression, and the tolerance to the stimulation will be documented. These aspects will assessed by means of the Barthel Index, the 7-item Hamilton Depression Scale, and a self-report questionnaire. Muscle activity of the paretic upper extremity will be measured with electromyography (EMG). All Parameters will be collected before and after the Intervention period, and 2 weeks after study treatment.	—

Measure

Time frame

As secondary outcome the independance in activities of daily living, depression, and the tolerance to the stimulation will be documented. These aspects will assessed by means of the Barthel Index, the 7-item Hamilton Depression Scale, and a self-report questionnaire. Muscle activity of the paretic upper extremity will be measured with electromyography (EMG). All Parameters will be collected before and after the Intervention period, and 2 weeks after study treatment.

—

Countries

Germany

Contacts

Public ContactCarmen Krewer

Schön Klinik Bad Aibling

CKrewer@schoen-kliniken.de08061 903 0

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026